Chinanews.com, Beijing, March 1. The "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2022)" (referred to as the "New Medical Insurance Drug Catalog") was officially implemented nationwide on March 1.
Bayer's Keshenda® (finerenone tablets), which is used to treat chronic kidney disease related to type 2 diabetes, was included, and the price dropped by nearly 80% from the original price of more than 400 yuan per box.
The inclusion of finerenone in the new version of the medical insurance catalog allows clinicians to formulate treatment plans for patients with high accessibility and double protection for the kidney and heart as soon as possible. It is of great significance to both doctors and patients in terms of clinical value and cost-effectiveness.
The relevant key phase III FIDELIO-DKD study showed that finerenone can continuously reduce proteinuria by 32%, and reduce the risk of cardiovascular composite endpoint events by 14% and the risk of renal composite endpoint events by 18%.
In addition, compared with the global data, the results of the Chinese subgroup of the FIDELIO-DKD study showed a trend of better renal benefits, which can reduce the risk of the main renal composite endpoint in Chinese patients with diabetes-related nephropathy by 41%, and at the same time have cardiovascular benefits.
There are about 130 million diabetics in China, of which more than 90% are type 2 diabetics.
At the same time, diabetes is closely related to chronic kidney disease. According to the "Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition)", about 40% of patients with type 2 diabetes will develop diabetes-related chronic kidney disease, which will easily lead to the occurrence of end-stage renal disease. , and greatly increase their risk of cardiovascular-related complications and death.
Clinically, there are no obvious symptoms in the early stage of kidney disease. Once overt proteinuria appears, it indicates that the course of the disease is progressing faster. If no timely intervention is made, late treatment will require dialysis to maintain life, which will bring heavy burdens to society and families. economic burden.
Keshenda® (finerenone tablets) is a non-steroidal selective mineralocorticoid receptor antagonist approved for marketing in China in June 2022 for the treatment of chronic kidney disease associated with type 2 diabetes adult patients.
(over)